Modifications of laboratory tests in patients treated with HeberFERON® for basal cell carcinoma
Keywords:
HeberFERON®, analytical modifications, adverse laboratory reactions.Abstract
Introduction: A combined formulation of alpha-2b and gamma interferon is a recent modality for the treatment of basal cell carcinoma. However, there are few reports exposing the modification of laboratory tests after their application.
Objective: To discover hemo-chemical alterations in subjects treated with HeberFERON®
Methods: An observational, descriptive and prospective research was conducted at the skin cancer clinic of the Teaching Polyclinic Carlos J. Finlay, in Colon, between January 2017 and December 2022. The sample included 88 patients with histological diagnosis of basal cell carcinoma. The dose was 10,5 million international units, administered by perilesional infiltration three times a week for three weeks. The variables explored were age, sex, weight, comorbidities, complementary tests values of weeks 0, 4, 8 and 16, intensity and recovery. Laboratory studies included hematocrit, platelet count, global and differential leucocyte count, cholesterol, triglycerides, transaminases, urea, creatinine, and uric acid. The SPSS 20.0 statistical package was used for data processing. The results are exposed in tables.
Results: Male patients and the 71 years and over age group predominated. More than half of the patients were hypertensive and overweight or obese. Hematocrit was the most altered parameter, followed by triglycerides and glomerular filtration. For this reason before, during and after the HeberFERON® treatment, hematological and chemical tests must be performed.
Conclusions: HeberFERON® caused slight and transient modifications of the laboratory tests, which corroborates being a safe medication.
Downloads
References
2. González-Sánchez N, Armada-Esmores Z, Llópiz-Casanova L. Propiedades de los interferones y su acción antitumoral. Medicent Electrón [Internet]. 2017 [citado 20/03/2024];21(3). Disponible en: https://www.medigraphic.com/pdfs/medicentro/cmc-2017/cmc173b.pdf
3. Ballester-Caballero Y, Rodríguez-Roja JL, Campollo-Rodríguez I, et al. Tratamiento con interferón alfa-2B recombinante en el carcinoma basocelular. Rev Electrón PortalesMédicos.com [Internet]. 2015 [citado 20/03/2024]. Disponible en: https://www.revista-portalesmedicos.com/revista-medica/tratamiento-con-interferon-alfa-carcinoma-basocelular/
4. Anasagasti-Angulo L, García-Vega Y, Barcelona-Pérez S, et al. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer [Internet]. 2009 [citado 23/03/2024];9:262. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/
5. CECMED. HEBERFERON® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec) [Internet]. La Habana: Centro de Ingeniería Genética y Biotecnología; 2022 [citado 02/08/2023]. Disponible en: https://www.cecmed.cu/registro/rcp/biologicos/heberferonr-interferon-alfa-2b-hu-rec-interferon-gamma-hu-rec?fbclid=IwAR311qZInNQ1L6vEbgaWUiHr-_404Pih16o08-KSnXCh5ax3zbqpC06n6vk
6. Departamento de Salud y Servicios Humanos de los Estados Unidos. Common Terminology Criteria for Adverse Events (CTCAE) [Internet]. Washington D. C: Departamento de Salud y Servicios Humanos de los Estados Unidos; 2010 [citado 02/08/2023]. Disponible en: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
7. García-García I, Hernández-González I, Díaz-Machado A, et al. Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha2b and gamma in healthy male volunteers. BMC Pharmacol Toxicol [Internet]. 2016 [citado 20/04/2024];17(1). Disponible en: http://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-016-0103-8
8. García-Vega Y, Anasagasti-Angulo L, Valenzuela-Silva C, et al. Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and Gamma (HeberPAG). J Clin Exp Ophthalmol [Internet]. 2015 [citado 20/04/2024];6(5). Disponible en: https://www.longdom.org/open-access-pdfs/retrospective-study-of-periocular-non-melanoma-skin-cancer-treated-with-thecombination-of-ifn-alpha2b-and-gamma-heberpag-2155-9570-1000478.pdf
9. García-Vega Y, García-García I, Collazo-Caballero SE, et al. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol [Internet]. 2012 [citado 23/04/2024];13:20. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633053/
10. Rojas-Rondón I, Vigoa-Aranguren L, García-Vega Y, et al. Seguridad del HeberFERON en pacientes con carcinoma basal palpebral. Rev Cubana Oftalmol [Internet]. 2021 [citado 23/02/2024];34(1). Disponible en: http://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/1131/874
11. Piña-Rodríguez Y, Monzón-Díaz Y, Piña-Russinyol JJ, et al. HeberFERON, experiencia en la provincia de Matanzas. Folia dermatol cuban [Internet]. 2019 [citado 23/02/2024];13(1). Disponible en: http://www.revfdc.sld.cu/index.php/fdc/article/view/146/168
12. Sánchez-Linares V, Ríos-Rodríguez ME, Román-Simón M, et al. HeberFERON en el carcinoma basocelular periocular. Serie de casos. Gac Méd Espirit [Internet]. 2021 [citado 23/02/2024];23(1):35-45. Disponible en: http://scielo.sld.cu/pdf/gme/v23n1/1608-8921-gme-23-01-35.pdf
13. Sánchez-Linares V, Brito-García E, Martínez-Fando B, et al. HeberFERON en el tratamiento de pacientes con carcinoma basocelular de la oreja. Gac Méd Espirit [Internet]. 2023 [citado 23/02/2024];25(2). Disponible en: http://revgmespirituana.sld.cu/index.php/gme/article/view/2530/0
14. Navarro Guarnizo EF, Zamora Suarez A, Ceron Tapia HR. Correlación entre las fórmulas de medición de filtrado glomerular Cockcroft-Gault, MDRD-4 y CKD-EPI, y la depuración de creatinina de 24 horas. Rev Colomb Nefrol. 2020;8(1):e458. DOI: 10.22265/acnef.8.1.458.
15. Sánchez-Linares V, Martínez-Fando B, Carpio-Muñoz E, et al. HeberFERON en el tratamiento de pacientes con carcinoma basocelular en zona de alto riesgo. Rev Cubana Med Gen Integr [Internet]. 2023 [citado 23/02/2024];39(3):e2693. Disponible en: http://scielo.sld.cu/pdf/mgi/v39n3/1561-3038-mgi-39-03-e2693.pdf
16. Rodríguez-Fonseca RA, de la Rosa-Santana JD, López-Wilson A, et al. Tratamiento con HeberFERON en pacientes con carcinoma basocelular del Hospital Docente Clínico Quirúrgico “Dr. Miguel Enríquez”, La Habana. Gaceta Médica Estudiantil [Internet]. 2020 [citado 23/02/2024];1(2):122-32. Disponible en: https://revgacetaestudiantil.sld.cu/index.php/gme/article/download/26/59/103
17. Rodríguez-Rosales S, Fonseca-Núñez YD, Fuentes-Gómez L, et al. Efectividad del HeberFERON en el tratamiento del carcinoma basocelular. Multimed [Internet]. 2023 [citado 23/02/2024];27. Disponible en: http://revmultimed.sld.cu/index.php/mtm/article/view/2515
18. Peña-Trujillo V, Alvis-Zakzuk NJ, Velásquez-Vargas MC, et al. Cáncer de piel: características clínicas, diagnóstico histopatológico y tratamiento en un centro dermatológico colombiano. Dermatol Rev Mex [Internet]. 2022 [citado 23/02/2024];66(1):38-47. Disponible en: http://dermatologiarevistamexicana.org.mx/article/cancer-de-piel-caracteristicas-clinicas-diagnostico-histopatologico-y-tratamiento-en-un-centro-dermatologico-colombiano/
19. Barazzetti DO, Barazzetti PHO, Cavalheiro BT, et al. Quality of life and clinical and demographic characteristics of patients with cutaneous squamous cell carcinoma submitted to tumor resection by double-bladed scalpel. An Bras Dermatol [Internet]. 2019 [citado 20/04/2024];94(3):304-12. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668942/
20. Dirección de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud 2022 [Internet]. La Habana: MINSAP; 2023 [citado 20/04/2024]. Disponible en: http://salud.msp.gob.cu/wp-content/Anuario/Anuario-2022.pdf
21. Fernández-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. MEDICC Review [Internet]. 2018 [citado 20/04/2024];20(1):11-7. Disponible en: https://www.scielosp.org/pdf/medicc/2018.v20n1/11-17
22. Vega-Abascal J, Álvarez-Fernández A, Ventura-Nieves K, et al. Tratamiento con HeberFERON del carcinoma basocelular en la Atención Primaria de Salud en Cuba. Rev Cubana Med Gen Integr [Internet]. 2021 [citado 23/02/2024];37(2):e1340. Disponible en: http://www.medigraphic.com/pdfs/revcubmedgenint/cmi-2021/cmi212t.pdf
23. Quintero Sarmiento DO, Ruiz Pedraza JA. Eventos adversos y problemas relacionados con medicamentos interferones reportados en Bogotá D.C. 2008 – 2017 [tesis en Internet]. Bogotá: Universidad de Ciencias Aplicadas Y Ambientales; 2018 [citado 23/02/2024]. Disponible en: https://repository.udca.edu.co/handle/11158/1003?locale-attribute=es
24. Viñals C, Zambón D, Yago G, et al. Hipertrigliceridemias secundarias. Clín investig arterioscler [Internet]. 2021 [citado 23/04/2024];33:29-36. Disponible en: http://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-pdf-S0214916821000395
25. de Francisco ALM. Efectos renales adversos del tratamiento del cáncer [Internet]. Macedonia del Norte: NefroPlus; 2019 [citado 23/04/2024]. Disponible en: http://nefrologiaaldia.org/es-articulo-efectos-renales-adversos-del-tratamiento-402
Downloads
Published
How to Cite
Issue
Section
License
All content published in this journal is Open Access, distributed under the terms of the CC BY-NC 4.0 License.
It allows:
- Copy and redistribute published material in any medium or format.
- Adapt the content.
This will be done under the following terms:
- Attribute the authors' credits and indicate whether changes were made, in which case it must be in a reasonable way.
- Non-commercial use.
- Recognize the journal where it is published.
The copyrights of each article are maintained, without restrictions.
Guidelines to authors
